RestructuringAug 13, 2026, 04:46 PM
Petros Pharma Q2 Loss $0.96M; Going Concern Doubt Amid Restructuring
AI Summary
Petros Pharmaceuticals reported a net loss of $0.96 million for the second quarter of 2026 and $1.94 million for the first half of 2026. The company disclosed substantial doubt about its ability to continue as a going concern due to recurring losses and insufficient liquidity. This follows a significant business restructuring in 2025, including the divestment of its Stendra® and VEDs businesses, and a strategic pivot towards developing an Rx-to-OTC switch technology platform. The company also restated prior period financials related to warrant valuations.
Key Highlights
- Substantial doubt raised about the company's ability to continue as a going concern.
- Reported net loss of $0.96 million for Q2 2026, and $1.94 million for H1 2026.
- Divested Stendra® and VEDs businesses in 2025, shifting to Rx-to-OTC platform.
- Cash and cash equivalents decreased to $3.49 million as of June 30, 2026.
- Total stockholders' equity declined to $0.70 million from $2.87 million.
- Restated Q2 2025 financials due to errors in warrant valuation.
- Basic and diluted loss per share from continuing operations was $(0.30) for Q2 2026.
Price Impact
More from PTPI